已收盤 11-20 16:00:00 美东时间
+0.010
+0.34%
11月18日,Lexeo Therapeutics(LXEO)收跌11.61%,报2.85美元,成交额1205.93万美元,市值2.36亿美元。 行情数据 •...
11-18 07:32
今日重点评级关注:康托·菲茨杰拉德:维持Lexeo Therapeutics"超配"评级,目标价从23美元升至37美元;摩根士丹利:维持Sana Biotechnology"超配"评级,目标价从12美元升至13美元
11-17 17:31
Lexeo Therapeutics, Inc. ( ($LXEO) ) has provided an update. On November 16, 20...
11-16 21:27
Lexeo Therapeutics (NASDAQ:LXEO) reported quarterly losses of $(0.43) per share which missed the analyst consensus estimate of $(0.33) by 30.3 percent. This is a 30.3 percent decrease over losses of $(0.33) per share from the same period last year.
11-16 20:02
Lexeo Therapeutics will report Q3 2026 financial results and provide an update on its HEROIC-PKP2 Phase I/II trial for LX2020, a gene therapy for PKP2 arrhythmogenic cardiomyopathy (ACM), on November 16, 2026. A webcast will be held at 8:00 AM ET, accessible via the company's website. LX2020, designed to deliver a functional PKP2 gene to cardiomyocytes, has received FDA designations including Regenerative Medicine Advanced Therapy and Fast Track....
11-15 12:00
11月10日,Lexeo Therapeutics(LXEO)收涨8.65%,报3.14美元,成交额416.38万美元,市值2.58亿美元。 行情数据 • 开盘...
11-10 07:33
11月3日,Lexeo Therapeutics(LXEO)收跌2.55%,报3.06美元,成交额373.37万美元,市值2.51亿美元。 行情数据 • 开盘价...
11-03 07:30
Lexeo Therapeutics announced multiple presentations at AHA and ICAR 2026, highlighting their cardiovascular and neurological gene therapy programs. Key updates include LX2006 demonstrating sustained neurologic and cardiac benefits in Friedreich ataxia, with mFARS scores improving by 2.13 points annually and further gains at 36 months. AHA presentations will showcase preclinical data on LX2021 for desmoplakin cardiomyopathy and LX2020 for TNNI3 ca...
11-02 12:00
10月27日,Lexeo Therapeutics(LXEO)收跌3.57%,报2.7美元,成交额314.95万美元,市值2.22亿美元。 行情数据 • 开盘价...
10-27 06:37
Lexeo Therapeutics will host an investor event on October 21, 2026, at 1:00 PM ET, discussing clinically meaningful arrhythmias in PKP2-ACM. Narinder Bhalla, M.D., Lexeo's Chief Medical Officer, and Alessio Gasperetti, M.D., Ph.D., a cardiologist specializing in inherited arrhythmias, will address key assessments, guideline-based approaches, and disease progression in PKP2-ACM. The event will be webcast live on Lexeo's website, with a replay avai...
10-19 11:00